Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,154 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose 0 Clear all
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

NCT02421367
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 49 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 5, 2026, 11:31 AM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

NCT01251952
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Denileukin Diftitox (Ontak)
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1 Interventional

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

NCT02840487
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA085-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Dronabinol (Oral THC) on Cannabis Use

NCT01394185
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Dronabinol 120mg/day, Placebo, Dronabinol 240mg/day
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 11:31 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
18
States / cities
Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

NCT02433652
View directory record Official record
Conditions
Dengue
Interventions
Recombinant live attenuated trivalent dengue vaccine, Placebo, rDEN2Δ30-7169 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Trial Of Double Umbilical Cord Blood Transplantation

NCT00763490
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
Procedure · Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

NCT01594424
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Tocilizumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT01599897
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
ID93 + GLA-SE, ID93 alone
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 5, 2026, 11:31 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 5, 2026, 11:31 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 11:31 AM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

NCT03794180
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
TJ003234, Placebo
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 5, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

NCT01399047
View directory record Official record
Conditions
Juvenile Neuronal Ceroid Lipofuscinosis
Interventions
Mycophenolate mofetil, Liquid Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
6 Years to 25 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 5, 2026, 11:31 AM EDT